ROCO
6661
Market cap12mUSD
Oct 07, Last price
17.20TWD
1D
1.47%
1Q
-5.75%
IPO
-33.90%
Name
Welgene Biotech Co Ltd
Chart & performance
P/E
301.38
P/S
1.07
EPS
0.06
Div yield, %
—
Shrs. gr., 5y
2.28%
Rev. gr., 5y
-1.14%
Revenues
376m
+16.55%
Net income
1m
+20.14%
CFO
35m
-37.11%
Dividend
Mar 16, 20230.18144 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Welgene Biotech Co.,Ltd. primarily focuses on delivering genetic analysis services. The company provides comprehensive support for scientific research, employing a range of advanced laboratory techniques such as genetic sequencing, microarray analysis, qPCR verification, nucleic acid extraction and quality control, LCM single cell experimentation, and intricate bioinformatics analysis. A key offering in their portfolio is Cytoscan, an array-based comparative genomic hybridization (CGH) solution. Beyond services, Welgene Biotech also supplies essential laboratory products, including various reagents, consumable items, and specialized instruments, alongside dedicated software solutions. Established in 2003, the company operates from its headquarters in Taipei City, Taiwan.
Key people
Fu Chian Chen
Chairman of the Board · since 2022
Yixing Lin
General Manager, Director · since 2022
Yanliang Li
Deputy General Manager · since 2005
Ying Jen Chen
Deputy General Manager-Management Division, Manager of Finance & Accounting, Director · since 2019
Guihong Chen
Chairman of the Board · since 2022
Yijing Guo
Director · since 2025
Jiaqi Lin
Director · since 2022
Independent Director · since 2017
Xiaomin Li
Independent Director · since 2017
Yanling Li
Independent Director · since 2025
Zhaoyuan Wu
Independent Director · since 2025
Yuncheng Yang
Independent Director · since 2025
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||